A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Cemiplimab in Patients with Advanced Cancers
Contact:
NCT Number:
Protocol:
AAAU1677
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The purpose of this study is to test the safety of the study drug, E-602, at different dose levels both alone (monotherapy) and in combination with pembrolizumab (also known as Keytruda®).Pembrolizumab is FDA-approved for the treatment of some cancers, but not all of the cancers in this study. E-602 has not been approved by the United States Food and Drug Administration (FDA). This study is the first time that E-602 will be administered to participants. The study will also inform on what effects, both good and bad, E-602 alone and in combination with pembrolizumab have on participants with advanced cancer.
Are you Eligible? (Inclusion Criteria)
- Are you aged 18 years or older?
- Do you have confirmed diagnosis of advanced cancer in which no standard therapy options are available?
- Do you not have a history of age-related macular degeneration (AMD)?
Specialty Area(s)
Breast Cancer, Esophageal Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Lung cancer, Melanoma, Pancreatic Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
